An observational study in Obesity, Metabolic Surgery and Bariatric Surgery, sponsored by Jinan University Guangzhou. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-02-23.
Sponsored by Jinan University Guangzhou · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.
Among the 603 studies in Obesity with a site in China, this one has the largest planned enrollment of the 99 observational ones that give a count, is one of 22 that started in 2020, is one of 99 observational ones, reaches primary completion later than 275 of the 282 other live ones, and was the 249th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 22 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000,000 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 120 across the 504 interventional studies, 320 across the 99 observational. Of the 242 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 603 have an industry lead sponsor. The 10 most frequent:
Jinan University Guangzhou is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Jinan University Guangzhou has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
106 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 106 to your calendar (.ics) → With an account.
Among the 603 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the Chinese Obesity and MEtabolic Surgery Database (COMES Database) is to collect data and examine the long-term effects of metabolic and bariatric surgery on obesity and metabolic disorders in the Chinese population.
COMES Database is a prospective managed national database to collect data and examine the long-term effects of metabolic and bariatric surgery on obesity and metabolic disorders in the Chinese population.
Patients diagnosed as obesity undergoing metabolic and bariatric surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
Procedure: Metabolic and Bariatric Surgery
Metabolic and bariatric surgery is weight loss surgery that results in weight loss and resolution of metabolic disorders.
Excess weight loss effect of metabolic and bariatric surgery after 1 year
Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]
Time frame: 1 year
Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups
Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]
Time frame: 3 years
Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups
Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]
Time frame: 5 years
Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups
Percent excess weight loss (%EWL) = \[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\]
Time frame: 10 years
Glycemic control effect of metabolic and bariatric surgery after 1 year
Change of HbA1c levels
Time frame: 1 year
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of HbA1c levels
Time frame: 3 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of HbA1c levels
Time frame: 5 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of HbA1c levels
Time frame: 10 years
Glycemic control effect of metabolic and bariatric surgery after 1 year
Change of blood glucose levels
Time frame: 1 year
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of blood glucose levels
Time frame: 3 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of blood glucose levels
Time frame: 5 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of blood glucose levels
Time frame: 10 years
Glycemic control effect of metabolic and bariatric surgery after 1 year
Change of C-peptide levels
Time frame: 1 year
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of C-peptide levels
Time frame: 3 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of C-peptide levels
Time frame: 5 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of C-peptide levels
Time frame: 10 years
Glycemic control effect of metabolic and bariatric surgery after 1 year
Change of insulin levels
Time frame: 1 year
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of insulin levels
Time frame: 3 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of insulin levels
Time frame: 5 years
Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups
Change of insulin levels
Time frame: 10 years
Adverse events rate of metabolic and bariatric surgery
Surgical safety by 30 days follow-up according to guideline
Time frame: 30 days after surgery
Plan to share: No
No publications or documents are linked to this record.
Started May 2020 (actual). Primary completion is estimated for Dec 2030, 127 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 127 months is above that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinan University Guangzhou